top of page

Are we ever going to see a cure ?

Oct 20
2 min read

Why do trials fail, why do new drugs take so long ?


Out of several potential treatments for Parkinson’s disease (PD) that have gone through clinical trials over the years most have turned out negative. This unfortunate situation represents disappointments for everyone — the study volunteers who went to considerable trouble and some risk to participate, the companies that lost money, the doctors who invested their time … and the Parkinson’s community as a whole, which has waited patiently through what seems to be a dismal lack of new Parkinson’s treatments since the discovery of levodopa almost a half-century ago.


It should be recognised that the problem is not something unique to PD. In other areas much more money has been spent, with fewer results, than it has in PD. The failure rate in all disease areas is a measure of the immense problem all scientists face in this extremely complex situation.


It should be recognised, however, that a negative finding is not the same as a failure. When we do get within sight of tomorrow’s “cures,” we will likely find ourselves standing on the shoulders of yesterday’s “failures.”


One of the reasons things move so slowly is that we need to know more about the basic science of PD. We have come a long way, but we still don’t understand enough about what causes it. The process would be much easier if we knew more about the origins and nature of the disease.


Another problem is that mice are frequently used to test new drugs, but mice don’t get PD. Humans are the only identifiable animals that get PD. What this means is that just because something works in a mouse or a monkey or some other animal doesn’t mean that it will work in a human.


It is being recognised that PD may not be just a single disease, but several. One implication of this is that a treatment that works for one group of people may not for another, for example, those who have specific genetic or clinical characteristics. More needs to be invested in identifying these subtypes and in finding economical ways of developing treatments to address them.


It has been suggested that we need to take a harder look at animal studies and early human trials before proceeding to the later and more expensive stages.


Finally there is a need for more sensitive and accurate markers of how PD progresses over time. The clinical observations of a doctor, even a very good one, are not sufficiently detailed to measure small changes in PD progression with the accuracy or speed that are needed to perform trials efficiently. It has been proposed that what is needed is a brain-based version of the global positioning system (GPS) that is used in a car — something that will tell doctors, using imaging techniques or chemical analysis of blood or spinal fluid, where exactly a person is in his or her Parkinson’s “journey,” and that will enable researchers to tell definitively whether an investigational drug is helping to slow or reverse the disease.


Taken from an observation by Robin Elliott, the Executive Director of the Parkinson's Disease Foundation. (PDF)

Recent Posts

See All
Safety Warning for levodopa/carbidopa drugs

FDA safety update (March 2026): vitamin B6 deficiency and seizures In March 2026 the FDA required a new label warning for all carbidopa/levodopa products — which includes Crexont and Vyalev above, as

 
 
 
Understanding Clinical Trial Phases

For patients and families following the research pipeline, understanding what each phase means helps set realistic expectations: Phase 1: Tests safety and dosing in a small number of participants (20-

 
 
 

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
Parkee, the impish character and uninvited guest.

To contact Snowy, you can provide your details here:

© 2026 by Stuart McDonnell. Powered and secured by Wix

bottom of page